Chemoradiation and consolidation chemotherapy for rectal cancer provides a high rate of organ preservation with a very good long-term oncological outcome: a single-center cohort series

Table 3 Studies using WW protocol after CRT-CNCT

Study	Patients, n	cT stage	Neoadjuvant protocol	CT regimen	RT Dose	^aClinical decision, weeks	cCR	^bRG	Follow-up, months	OS/DFS
Rettig et al. [19]	66	T1: 1 (1.50%) T2: 9 (13.6%) T3: 50 (75.8%) T4: 6 (9.10%)	CRT-CNCT (84%) INCT-CRT (16%)	8 FOLFOX 6 CAPEOX	50.4 Gy	20–22	55%	19%	30	86%/NR
Garcia-Aguilar et al. [12]	158	T1–2: 13 (12%) T3: 82 (77.0%) T4: 11 (10.0%)	CRT-CNCT	8 FOLFOX 5 CAPEOX	50–56 Gy	28.5	75%	19%	36	NR/76%
Habr-Gama et al. [20]	126	T1: 0. (0.00%) T2: 27 (55.0%) T3: 20 (40.8%) T4: 2 (4.20%)	CRT-CNCT	6 cycles 5FU+Leucovorin	54 Gy	10	63%	27%	NR	NR/NR
Habr-Gama et al. [21]	69	T1: 0 (0.00%) T2: 20 (28.6%) T3: 47 (67.1%) T4: 3 (4.30%)	CRT-CNCT	6 cycles 5FU+Leucovorin	50.4 Gy	10	68%	25%	56	90%/72%
Present Study	60	T1: 0 (0.00%) T2: 0 (0.00%) T3: 43 (72.0%) T4: 17 (18.0%)	CRT-CNCT	6 FOLFOX 6 XELOX	50.4 Gy	20–26	65%	25%	63	90.1%/71.6%

cCR complete clinical response, CRT-CNCT chemoradiotherapy-consolidation chemotherapy, CT chemotherapy, DFS disease-free survival, INCT-CRT induction chemotherapy-chemoradiotherapy, NR non reported, OS overall survival, RG regrowth, RT radiotherapy, WW watch-and-wait protocol
^aTime interval end of radiotherapy and reassessment
^bRatio of patients with RG to total patients in the WW protocol

ISSN: 1477-7819